ImmunoCellular Therapeutics (OTC:IMUC) said Tuesday that its CEO, Manish Singh, will speak at the Phacilitate Immunotherapy Leaders' Forum 2012, in Barcelona, Spain.
Dr. Singh will speak at the forum taking place from May 9-11, and
will deliver the Chair’s introductory presentation titled: "A
retrospective of the past 15 years of novel immunotherapy products— from
Rituxan™ to Adcetris™," to begin at 9:00 am local time on Wednesday May
The Phacilitate Immunotherapy Leaders' Forum is an annual gathering
place for senior executives and scientists driving the development of
immunotherapies. The event is focused on overcoming the challenges
involved in bringing these technologies to the market.
ImmunoCellular is a clinical-stage biotech company based in Los
Angeles. The company focuses on the development of new immune-based
products in the treatment and diagnosis of brain and other cancers.
A phase II trial recently started on the company's leading product
candidate, ICT-107, a dendritic cell-based vaccine that targets multiple
tumour-associated antigens for glioblastoma, an aggressive form of
This is done by removing dendritic cells from a patient, loading them
with the tumour-related antigens, and re-injecting them back into the
patient's body to trigger an immune response against cancer cells
exhibiting these antigens.
Rather than simply targeting a single tumour-specific antigen, IMUC’s
vaccine tracks multiple different antigens found on cancer stem cells.
Cancer stem cells are thought to be the originators of common tumour
cells, and lead to cancer’s re-growth after chemotherapy. It is believed
that destroying the cancer stem cells will allow for longer survival,
Details of the conference may be found at http://www.phacilitate.co.uk/event.php?eid=12&pid=282